Jivial Industries IPO Review — Should You Apply?
Weak Demand Signals
Negative or zero grey market premium and low subscription indicate weak market sentiment.
Jivial Industries IPO Review Summary
Jivial Industries paired excellent quality with tiny scale — a 31.23% EBITDA margin and 46.79% ROCE, but on just ₹12.11 Cr of revenue and at a full 23.29x fixed price. The market balked, sending it about 20% below issue on debut.
This was a case of strong ratios not justifying a full price on a micro-cap. It suited only risk-tolerant investors; compare it on our IPO performance page. This is informational analysis based on available data, not investment advice.
Who Should Consider This IPO?
This IPO suited high-risk-tolerant investors drawn to strong margins and returns who could look past minimal scale and a full price. New to applying? Our how to apply for an IPO guide helps.
It was unsuited to value or conservative investors, given the 23.29x valuation, tiny size, and the weak debut. Applications go through a discount demat account via UPI.
Detailed Investment Analysis
As a fixed-price issue at ₹196, Jivial was valued at 23.29x earnings on a post-issue EPS of ₹8.42 — a fairly full multiple for a very small manufacturer, which prices in continued strong execution.
The financial quality genuinely stands out for the size. A 31.23% EBITDA margin is high and suggests real product differentiation, while the 41.09% RONW and 46.79% ROCE show excellent capital efficiency. The catch is scale: at just ₹12.11 Cr of revenue, this is a micro-cap where a single order or client can swing the numbers.
The risks are those of tiny businesses at full valuations. Minimal scale makes growth lumpy and fragile, the high margins and returns are hard to sustain as the company grows, and a 23.29x price leaves little room for missteps. Client concentration is another likely factor.
The market was cautious: the stock listed weakly at ₹156.80 against its ₹196 issue price — a drop of roughly 20% — underscoring that the full valuation and small size outweighed the strong ratios on debut. Our IPO profit calculator can size a position. Investors should consult a SEBI-registered financial advisor before making investment decisions.
Strengths
- An excellent 31.23% EBITDA margin, pointing to a differentiated, value-added product rather than a commodity line.
- Standout return ratios, with RONW of 41.09% and ROCE of 46.79% showing strong capital efficiency.
- Mostly a fresh issue, with ₹26.65 Cr of new capital going into the company for growth.
- A simple, transparent fixed-price structure at ₹196 with no band ambiguity.
- Genuine profitability for the size, with a ₹2.95 Cr net profit on ₹12.11 Cr revenue.
Risks & Concerns
- A weak debut — the stock listed at ₹156.80, about 20% below its ₹196 issue price.
- A full valuation at 23.29x earnings, demanding for a company this small.
- Very minimal scale, with revenue of just ₹12.11 Cr, makes growth lumpy and the business fragile.
- The high margins and 46.79% ROCE are difficult to sustain as the equity base grows post-raise.
- Thin SME liquidity and likely client concentration amplify the risk profile.
Want Full IPO Data?
This review focuses on analysis. For complete IPO details — GMP history, subscription day-wise, financial tables, allocation breakdown, and registrar/lead manager info — visit the full data page.
View Jivial Industries IPO Full Details →Frequently Asked Questions
What was Jivial Industries IPO's price and lot size?
Jivial Industries was a fixed-price issue at ₹196 per share, with a lot of 600 shares — a per-lot value of about ₹1.18 lakh. The face value was ₹10.
Is Jivial Industries a fixed-price or book-built IPO?
It was a fixed-price issue at ₹196 per share, which is why there is a single price rather than a band.
How did Jivial Industries perform on listing?
Weakly — the stock listed at ₹156.80 against its ₹196 issue price, a drop of roughly 20%, as the full valuation outweighed its strong ratios.
How strong are Jivial Industries' financials?
High-quality but small: a 31.23% EBITDA margin and return ratios of 41.09% RONW and 46.79% ROCE, on revenue of just ₹12.11 Cr.
Disclaimer: This review is informational analysis based on publicly available data. It is NOT investment advice. The verdict is a data-driven signal, not a recommendation to buy or sell. IPO GMP is unofficial and unregulated. Consult a SEBI-registered financial advisor before making investment decisions. Stock market investments are subject to market risks.